Focused ultrasound ablation offer prostate cancer option

January 1, 2009 Diagnostic Imaging. Vol. 31 No. 1 Focused ultrasound ablation offer prostate cancer option BY CLARE TEMPANY, M.D., JALIL AFNAN, M.D., AND NATHAN MCDANNOLD, PH.D. Dr. Tempany is a professor of radiology, Dr. Afnan is a research fellow, and Dr. McDannold is an assistant professor of radiology and codirector of the Focused Ultrasound Research Laboratory, all in the department of radiology at Brigham and Women's Hospital, and Harvard Medical School in Boston. All are also affiliated with the National Center for Image Guided Therapy, supported by the NIH. Prostate cancer is a leading cause of cancer death in U.S. men, second only to lung cancer. During 2008, an estimated 186,320 new cases of prostate cancer will be diagnosed in the U.S. Approximately one in six men will be diagnosed with and one in 34 will die of prostate cancer.1 Once a diagnosis is made, the extent or stage of the disease must be determined before treatment decisions are made. The most critical issue is whether the tumor is confined to the prostate gland itself or extends beyond.

See full article and related articles at DiagnosticImaging.com
This article was republished with permission from CMPMedica, LLC